Close

Impax, Perrigo to jointly develop topical generic drug

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Indian Pharma Grows 8% CAGR, Surpassing Global Average

The Indian pharma sector has seen 8% CAGR growth...

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Impax Laboratories and Perrigo Company have signed a deal to develop and manufacture an undisclosed topical generic drug.

The terms of the deal that also involves marketing of the extended topical generic product were not revealed.

Impax Laboratories president and CEO Larry Hsu said, “In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development.”

Impax applies its formulation expertise and drug delivery technology in the invention of controlled-release and specialty generics besides branded drugs.

Perrigo chairman, president and CEO Joseph Papa said, “We are pleased to be partnering with Impax on this opportunity to be first to market with this important new product, making quality healthcare more affordable for our customers as quickly as possible.”

 

Latest stories

Related stories

Indian Pharma Grows 8% CAGR, Surpassing Global Average

The Indian pharma sector has seen 8% CAGR growth...

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back